These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 31924522)

  • 1. In vitro effect of an antimicrobial combination therapy without colistin and tigecycline for CPE and non-CPE.
    Okanda T; Matsumoto T
    J Infect Chemother; 2020 Apr; 26(4):322-330. PubMed ID: 31924522
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Cebrero-Cangueiro T; Álvarez-Marín R; Labrador-Herrera G; Smani Y; Cordero-Matía E; Pachón J; Pachón-Ibáñez ME
    Front Cell Infect Microbiol; 2018; 8():363. PubMed ID: 30406040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.
    Marimuthu K; Ng OT; Cherng BPZ; Fong RKC; Pada SK; De PP; Ooi ST; Smitasin N; Thoon KC; Krishnan PU; Ang MLT; Chan DSG; Kwa ALH; Deepak RN; Chan YK; Chan YFZ; Huan X; Zaw Linn K; Tee NWS; Tan TY; Koh TH; Lin RTP; Hsu LY; Sengupta S; Paterson DL; Perencevich E; Harbarth S; Teo J; Venkatachalam I;
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant
    El-Mahallawy HA; El Swify M; Abdul Hak A; Zafer MM
    Ann Med; 2022 Dec; 54(1):1-9. PubMed ID: 36373970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.
    Livermore DM; Warner M; Mushtaq S; Doumith M; Zhang J; Woodford N
    Int J Antimicrob Agents; 2011 May; 37(5):415-9. PubMed ID: 21429716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
    García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R;
    Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Molecular Characteristics of Carbapenemase-Producing Enterobacteriaceae From Five Hospitals in Korea.
    Jeong SH; Kim HS; Kim JS; Shin DH; Kim HS; Park MJ; Shin S; Hong JS; Lee SS; Song W
    Ann Lab Med; 2016 Nov; 36(6):529-35. PubMed ID: 27578505
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Zhou C; Wang Q; Jin L; Wang R; Yin Y; Sun S; Zhang J; Wang H
    Front Microbiol; 2020; 11():533209. PubMed ID: 33193122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo Effect of Antimicrobial Agent Combinations Against Carbapenem-Resistant
    Liu E; Jia P; Li X; Zhou M; Kudinha T; Wu C; Xu Y; Yang Q
    Infect Drug Resist; 2021; 14():917-928. PubMed ID: 33707959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular and epidemiological characteristics of carbapenemase-producing Enterobacteriaceae isolated from children in Shanghai, China, 2016-2021.
    Fu P; Luo X; Shen J; He L; Rong H; Li C; Chen S; Zhang L; Wang A; Wang C
    J Microbiol Immunol Infect; 2023 Feb; 56(1):48-56. PubMed ID: 35987725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers.
    Huang TD; Poirel L; Bogaerts P; Berhin C; Nordmann P; Glupczynski Y
    J Antimicrob Chemother; 2014 Feb; 69(2):445-50. PubMed ID: 24055766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK).
    Woodford N; Xu-McCrae L; Mushtaq S; Wu HHT; Ellington MJ; Lancaster O; Davies F; Donaldson H; Rao GG; Verma A; Wareham DW; Ciesielczuk H; Stone GG; Irani PM; Bracher S; Hawkey PM
    J Antimicrob Chemother; 2018 Mar; 73(3):698-702. PubMed ID: 29253163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid detection method of carbapenemase-producing Enterobacteriaceae by MALDI-TOF MS with imipenem/cilastatin (KB) disc and zinc sulfate solution.
    Oho M; Funashima Y; Nagasawa Z; Miyamoto H; Sueoka E
    J Infect Chemother; 2021 Feb; 27(2):205-210. PubMed ID: 33008738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center.
    Kulengowski B; Burgess DS
    Pathog Dis; 2019 Jun; 77(4):. PubMed ID: 31365075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae.
    Hayakawa K; Nakano R; Hase R; Shimatani M; Kato H; Hasumi J; Doi A; Sekiya N; Nei T; Okinaka K; Kasahara K; Kurai H; Nagashima M; Miyoshi-Akiyama T; Kakuta R; Yano H; Ohmagari N
    J Antimicrob Chemother; 2020 Mar; 75(3):697-708. PubMed ID: 31789374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.